Analyst Ratings January 28, 2026

Truist Reaffirms Buy on Meta, Sets $875 Target After Strong Q4 Results

Analysts point to robust margins and aggressive 2026 investments even as expenses rise; revenue and guidance beat consensus

By Derek Hwang META GLW
Truist Reaffirms Buy on Meta, Sets $875 Target After Strong Q4 Results
META GLW

Truist Securities reiterated a Buy rating on Meta Platforms with a $875 price target following the company’s fourth-quarter 2025 results. Meta reported revenue and profitability metrics that outpaced consensus, provided above-street first-quarter guidance, and set elevated 2026 capital and operating spending plans tied to its Meta Superintelligence Labs and core business.

Key Points

  • Meta beat Q4 revenue and operating income estimates and maintained an 82% gross profit margin.
  • Company set elevated FY2026 capex ($115-135B) and operating expense guidance ($162-169B) tied to Meta Superintelligence Labs and core investments, while forecasting higher operating income in 2026 than 2025.
  • Analysts broadly remain positive - Truist reiterated Buy with an $875 target; other firms kept targets between $800 and $870, while Goldman Sachs maintained a Buy with an $815 target.

Truist Securities has reiterated a Buy rating on Meta Platforms Inc. and assigned an $875.00 price target in the wake of the company's fourth-quarter 2025 financial report. The affirmation follows results that largely exceeded Wall Street expectations on revenue and operating income, while management outlined a substantially higher investment profile for fiscal 2026.

Quarterly performance and margins

Meta posted fourth-quarter revenue growth of 24% year-over-year, beating consensus expectations of 21% and remaining slightly under the 26% increase the company recorded in the third quarter. On a foreign-exchange-neutral basis, growth was 23%, down from 25% in the prior quarter. Ad impressions rose 18% year-over-year, and the average price per ad increased 6%.

The company sustained a strong gross profit margin, registering an impressive 82% over the last twelve months. Operating income for the quarter was $24.7 billion, equal to a 41% operating margin, modestly ahead of consensus estimates of $23.9 billion. Meta's revenue growth measured 21.3% over the last twelve months, with a five-year revenue compound annual growth rate of 18% as reflected in the underlying data.

Daily Active People reached 3.58 billion, up 7% year-over-year, underscoring continued user engagement. Meta's current ratio stood at 1.98, suggesting that liquid assets exceed short-term liabilities by a comfortable margin.

Capital spending and guidance for 2026

Capital expenditures in the quarter totaled $21.4 billion, slightly below Street expectations of $21.8 billion. For fiscal year 2026, Meta set capital expenditure guidance of $115-135 billion, which implies 79% year-over-year growth at the midpoint. The company attributed the higher capex to increased investments in its Meta Superintelligence Labs and its core business.

Alongside capex guidance, Meta provided initial full-year 2026 operating expense guidance of $162-169 billion, representing a 56% year-over-year increase. Despite the elevated spending trajectory, management expects operating income in 2026 to exceed 2025 levels.

For the first quarter of 2026, Meta projected revenues between $53.5 billion and $56.5 billion, surpassing consensus expectations of $51.4 billion and implying approximately 30% year-over-year growth at the midpoint.

Valuation and financial position

Meta is trading with a price-to-earnings ratio of 29.65. Analysts' consensus recommendation remains strongly positive, with a 1.33 score on the scale where 1 denotes Strong Buy. The company's market capitalization was $1.69 trillion, and it operates with a moderate debt profile - a debt-to-equity ratio of 0.26 - leaving it with financial flexibility to support its planned investments.

At a current share price of $668.73, Meta sits below some analysts' high targets of $1,117, reflecting a range of expectations across the sell side.

Wall Street reactions and other analyst views

Goldman Sachs reacted positively to Meta's fourth-quarter results and guidance, maintaining a Buy rating and a $815 price target. Several other firms reiterated constructive stances, including Wolfe Research and Bernstein SocGen Group, which held price targets ranging from $800 to $870, while noting concerns over increased spending on artificial intelligence.

Wolfe Research specifically forecasts 21% year-over-year revenue growth for Meta in 2026, above the broader Street estimate of 18.5% cited in the underlying data.

Other corporate and legal developments noted

In separate corporate news, BofA Securities raised its price target for Corning to $120 from $110 while maintaining a Buy rating after Corning's quarterly results. Corning's revenue modestly exceeded expectations thanks to stronger performance in its Display and Hemlock segments, though it fell short in the Optical segment.

Additionally, a legal matter outside the public-company reporting landscape resolved when TikTok settled a social media addiction lawsuit with a 19-year-old California plaintiff, thereby avoiding one of three so-called bellwether trials related to similar claims against social media platforms.


Summary

Truist Securities kept a Buy rating and $875 price target on Meta after the company reported fourth-quarter 2025 results that beat revenue and operating income estimates, sustained high gross margins, and provided first-quarter revenue guidance above consensus. Management outlined materially higher capital and operating expenditures for 2026 linked to investments in Meta Superintelligence Labs and core operations, while reaffirming expectations for higher operating income year-over-year despite the increased spending.

  • Key points
    • Meta outperformed consensus on Q4 revenue and operating income and reported an 82% gross profit margin over the last twelve months.
    • Management guided Q1 2026 revenue above Street expectations and set substantial FY2026 capex and operating expense ranges tied to investments in Meta Superintelligence Labs and core business.
    • Analysts broadly maintained positive ratings and price targets, with some concern noted about higher AI-related spending; Meta remains well capitalized with a market cap of $1.69 trillion and a debt-to-equity ratio of 0.26.
  • Risks and uncertainties
    • Increased operating and capital expenditures for 2026 - particularly related to Meta Superintelligence Labs - raise execution and return risks for the company and could pressure margins if investments do not generate expected returns; this impacts technology and AI sectors as well as investor sentiment in equity markets.
    • Higher spending on artificial intelligence prompted some analyst concern; elevated costs may affect near-term profitability and valuation metrics in the technology and advertising sectors.
    • Guidance and forecasts vary across firms, and a notable range exists between some analysts' high targets and current trading levels, which introduces uncertainty for equity investors.

For readers: The company has signaled a strategic shift toward heavier capital deployment in 2026 while providing confidence that operating income should remain higher than the prior year, a balance investors and analysts will be watching closely as the fiscal year unfolds.

Risks

  • Substantially higher 2026 operating and capital expenditures increase execution and return risks for Meta and could pressure margins if investments underperform, affecting technology and AI sectors.
  • Analyst concern about elevated AI-related spending introduces near-term profitability uncertainty and could influence investor sentiment in the advertising and tech equity markets.
  • Divergent price targets and forecasts across analysts create valuation uncertainty for equity investors given current share price versus high targets.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026